Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.

Name: Αlpha¹ Rigor Record — Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Item: Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Rating: 100
Author: Αlpha¹

Datoo MS, Dicko A, Tinto H, Ouédraogo JB, Hamaluba M, Olotu A, Beaumont E, Ramos Lopez F, Natama HM, Weston S, Chemba M, Compaore YD, Issiaka D, Salou D, Some AM, Omenda S, Lawrie A, Bejon P, Rao H, Chandramohan D, Roberts R, Bharati S, Stockdale L, Gairola S, Greenwood BM, Ewer KJ, Bradley J, Kulkarni PS, Shaligram U, Hill AVS, R21/Matrix-M Phase 3 Trial Group

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.75★ (Adequate), 0 critical, 1 high issue for “Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.75 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
CitationsUnresolved reference−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No data or code availability links were detected to verify.

Problems surfaced3 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

Broken references and links1

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported phase 3 randomized controlled trial of the R21/Matrix-M malaria vaccine. The paper demonstrates strong scientific premise, rigorous design, comprehensive reporting of biological variables, ethical approvals, key resources, statistical analysis, data availability, and transparency. Minor issues include a few copyediting inconsistencies and a single reference that could not be found in registries.

Both reviewers independently scored all eight dimensions and agreed on every status. The study type is interventional (phase 3 RCT). The statistics verification recomputed 8 reported tests consistently; the citation check flagged 1 reference not found in registries; the integrity check noted a minor discrepancy in Table 2 (N=3102 vs 3103) that is likely a rounding issue.

6 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 8 tests: 8 consistent, 0 inconsistent; 8 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites prior work on RTS,S/AS01 and R21/Matrix-M, acknowledging both strengths (efficacy) and limitations (insufficient supply, waning efficacy). The rationale for the trial is clearly stated: to assess efficacy in an extended age range (5-36 months) and with different transmission settings. The paper also addresses limitations of prior research, such as the need for a low-cost, high-efficacy vaccine with scalable supply.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper establishes a strong scientific premise by citing prior malaria vaccine research, including RTS,S/AS01 and phase 2b trials of R21/Matrix-M, and clearly links this to the study's objectives.

Evidence

direct quote[Introduction, paragraph 1]

“In the phase 3 trial of RTS,S/AS01, a circumsporozoite protein-based vaccine, vaccine efficacy in children aged 5–17 months with a four-dose regimen was 56% over 1 year and 36% over 4 years.”